mProX™ Human MAPK1 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

MAPK1 (also known as ERK2) is involved in various applications. In the study on Talaroconvolutin-A (TalaA) and bladder cancer, MAPK1 was found to be one of the MAPKs that TalaA binds to, inhibiting the phosphorylation of transcription regulators. This suggests that MAPK1 plays a role in the mechanism of TalaA in suppressing bladder cancer by targeting MAPKs, suppressing the cell cycle, and inducing ferroptosis. In the study on α-solanine and glioma, MAPK1 was identified as one of the hub genes and was associated with the effect of α-solanine on glioma. The study on extracellular vesicles from severe acute pancreatitis-associated lung injury patients found that miR-483-5p and miR-503-5p targeted MAPK1 in the regulation of severe acute pancreatitis-associated lung injury. Finally, in the study on Polygonum perfoliatum L. and non-alcoholic fatty liver disease (NAFLD), MAPK1 was identified as one of the key targets of PPL in the treatment of NAFLD. These studies suggest that MAPK1 is involved in the regulation of bladder cancer, glioma, severe acute pancreatitis-associated lung injury, and NAFLD.